Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR7 | Q9NYK1 | 19/20 | 0.81 |
| ▸ | TLR8 | Q9NR97 | 13/20 | 0.81 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.81 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29663892 | 1.00 | TLR7 (0.81) | TLR7TLR8NUDT1 | |
| Resiquimod SCHEMBL34159 | 0.89 | TLR7 (1.00) | TLR7TLR8NUDT1 | |
| Resiquimod SCHEMBL21352711 | 0.89 | TLR7 (1.00) | TLR7TLR8NUDT1 | |
| SCHEMBL24880278 | 0.89 | TLR7 (0.88) | TLR7TLR8NUDT1 | |
| Resiquimod SCHEMBL29358122 | 0.89 | TLR7 (1.00) | TLR7TLR8NUDT1 | |
| SCHEMBL20199817 | 0.89 | TLR7 (1.00) | TLR7TLR8NUDT1 | |
| Resiquimod SCHEMBL2262583 | 0.88 | TLR7 (0.98) | TLR7TLR8NUDT1 | |
| Resiquimod SCHEMBL2266073 | 0.88 | TLR7 (0.98) | TLR7TLR8NUDT1 | |
| SCHEMBL675585 | 0.88 | TLR7 (0.85) | TLR7TLR8NUDT1 | |
| SCHEMBL22898837 | 0.88 | TLR7 (0.65) | TLR7TLR8NUDT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114364677-B | Imidazo [4,5-C ] pyridine derivatives as TOLL-like receptor agonists | 辉瑞公司 | 2024-07-09 | — | — | CN | claimed |
| WO-2023079428-A1 | COMBINATION THERAPIES USING TLR7/8 AGONIST | PFIZER INC. (US) | 2023-05-11 | — | — | WO | claimed |
| CN-114364677-A | Imidazo [4,5-C ] pyridine derivatives as TOLL-like receptor agonists | 辉瑞公司 | 2022-04-15 | — | — | CN | claimed |
| CN-114364677-B | Imidazo [4,5-C ] pyridine derivatives as TOLL-like receptor agonists | 辉瑞公司 | 2024-07-09 | — | — | CN | disclosed |
| WO-2023079428-A1 | COMBINATION THERAPIES USING TLR7/8 AGONIST | PFIZER INC. (US) | 2023-05-11 | — | — | WO | disclosed |
| US-11339159-B2 | Toll-like receptor agonists | PFIZER INC. (US) | 2022-05-24 | — | — | US | disclosed |
| CN-114364677-A | Imidazo [4,5-C ] pyridine derivatives as TOLL-like receptor agonists | 辉瑞公司 | 2022-04-15 | — | — | CN | disclosed |
| US-20210017172-A1 | TOLL-LIKE RECEPTOR AGONISTS | PFIZER INC. (US) | 2021-01-21 | — | — | US | disclosed |
| WO-2021009676-A1 | IMIDAZO[4,5-C]PYRIDINE DERIVATIVES AS TOLL-LIKE RECEPTOR AGONSITS | PFIZER INC. (US) | 2021-01-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210017172-A1 | TOLL-LIKE RECEPTOR AGONISTS | TLR3, TLR1, TLR4 | TLR7 4/4885TLR8 9/4885NUDT1 1476/4885 |
| US-11339159-B2 | Toll-like receptor agonists | TLR3, TLR1, TLR4 | TLR7 4/4885TLR8 9/4885NUDT1 1476/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.